Imago Biosciencesincwas A Clinical Stage Biopharmaceutical Company Based In South San Franciscocaliforniafocused On Developing Therapies For Bone Marrow Diseases And Hematologic Cancersfounded In 2012Imago Specialized In Targeting Lysine Specific Demethylase 1Lsd1 An Enzyme Important For Blood Cell Productionin November 2022The Company Was Acquired By Merck & Co Incfor Approximately $1 35 Billion And Now Operates As A Subsidiary Of Merck Imago S Lead Candidatebomedemstatimg 7289 Is An Oral Lsd1 Inhibitor That Has Been Evaluated In Multiple Phase 2 Trials For Conditions Such As Essential Thrombocythemiamyelofibrosisand Polycythemia Veraamong Othersthe Company Aimed To Address Unmet Medical Needs In Myeloproliferative Neoplasms And Related Disorders Through Innovative Small Molecule Therapiesfollowing Its Acquisitionimago S Research And Development Efforts Have Been Integrated Into Merck S Hematology Portfolioenhancing Their Capabilities In This Field
